ChartMill assigns a fundamental rating of null / 10 to TKAI.
ChartMill assigns a valuation rating of null / 10 to Tokai Pharmaceuticals Inc. (TKAI). This can be considered as Overvalued.
Tokai Pharmaceuticals Inc. (TKAI) has a profitability rating of null / 10.
The financial health rating of Tokai Pharmaceuticals Inc. (TKAI) is null / 10.
The Earnings per Share (EPS) of Tokai Pharmaceuticals Inc. (TKAI) is expected to decline by -3.48% in the next year.